about
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistanceRecent advances in the understanding of antibiotic resistance in Clostridium difficile infectionTracking Change: A Look at the Ecological Footprint of Antibiotics and Antimicrobial ResistanceConformational analysis of Clostridium difficile toxin B and its implications for substrate recognitionAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionClostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventionsDissemination of Clostridium difficile in food and the environment: Significant sources of C. difficile community-acquired infection?[Current data and trends on the development of antibiotic resistance of Clostridium difficile].Array comparative hybridisation reveals a high degree of similarity between UK and European clinical isolates of hypervirulent Clostridium difficile.A high-throughput small-molecule screen to identify a novel chemical inhibitor of Clostridium difficile.Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiotaCharacterization of a stable, metronidazole-resistant Clostridium difficile clinical isolateConfocal laser endomicroscopy for in vivo diagnosis of Clostridium difficile associated colitis - a pilot studyAntibacterial effect of Manuka honey on Clostridium difficile.In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficileMolecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A⁻B⁺ isolates and increase of A⁺B⁺ isolates.Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China.Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Clostridium difficile drug pipeline: challenges in discovery and development of new agentsInnate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection.Antimicrobial-resistant strains of Clostridium difficile from North America.Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in TaiwanAntimicrobial resistance, toxinotype, and genotypic profiling of Clostridium difficile isolates of swine origin.Clostridium difficile infections in China.Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaksThe economic burden of Clostridium difficile.Clostridium difficile infection in the twenty-first century.Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.Toxinotyping and Sequencing of Clostridium difficile Isolates from Patients in a Tertiary Care Hospital of Northern India.Novel avenues for Clostridium difficile infection drug discovery.Genomic study of the Type IVC secretion system in Clostridium difficile: understanding C. difficile evolution via horizontal gene transfer.Disruption of intrinsic motions as a mechanism for enzyme inhibition.Crystal structures of two nitroreductases from hypervirulent Clostridium difficile and functionally related interactions with the antibiotic metronidazole.Antimicrobial Susceptibility Patterns of Clostridium difficile Isolates from Family Dairy Farms.Draft Genome Sequence of Clostridium difficile Strain IT1118, an Epidemic Isolate Belonging to the Emerging PCR Ribotype 018.Replacement of Soybean Meal with Animal Origin Protein Meals Improved Ramoplanin A2 Production by Actinoplanes sp. ATCC 33076.Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro.Comparison of supplemented Brucella agar and modified Clostridium difficile agar for antimicrobial susceptibility testing of Clostridium difficile.Demonstration of conjugative transposon (Tn5397)-mediated horizontal gene transfer between Clostridium difficile and Enterococcus faecalis.
P2860
Q24632641-5AB8FD61-EB24-4AE6-B563-F411C10AA601Q26767079-C92038B4-A49C-4C8C-A020-1D6E5C4283FEQ27007076-38DB4476-CBD8-4801-95A6-D1C6F6965CE0Q27331744-8DC580E7-BC47-4E7E-A6E8-72F2B6E33F1BQ28084026-1CA62A6F-FE26-4AF8-9C8B-E68038DC0CD0Q28743438-5FE00E64-DD60-47A3-9EAD-F4F9254CB7F8Q30241810-52249B29-03A4-4641-A293-3C73BC341392Q30575525-FD62B232-0F61-46B8-A113-E34F92F91206Q33611474-5F541DDA-E6BC-4CB4-AD13-6252BD3EE2A1Q33774194-EF1201B3-B205-4DDB-8C88-3705FE4182D8Q34097514-FC5A390D-0900-4120-AC22-DE28BC4168FFQ34562315-487539C9-3EA5-4B57-B6C5-D40BB64C2F2DQ34634266-E3375B42-5214-42FA-99A9-D780F14AF414Q34708981-B7704DFA-3DB6-4FAC-98A6-2E84A1C82ED3Q34737357-3805EE8D-F6B5-4A25-A3F5-A3FF14BFB390Q35014457-036448A9-E237-4128-B467-C4E0310AE91DQ35035736-D578EB77-57B4-462D-97C1-17ACE7111E87Q35364406-2DF54AC3-6115-4837-82C0-96047FF66D3DQ35491398-21DD6A59-06BD-4BCD-9623-0BD681500E52Q35846436-5F7F0C15-B5E8-43E0-81B2-1D8E6886C7ECQ35957398-EB0A65F0-C3E2-4742-87DC-61D0E1D0B941Q36018766-CA098BCB-60F3-458A-AF78-D770EC368585Q36086377-9D7A78F8-E5F0-4261-8EB0-8E899FBB44EFQ36118699-336A1877-3750-4259-97B8-0FED54999CC6Q36681933-1020E95B-3642-4372-830C-21D6B029C6D2Q36970016-781CDEE4-ED21-42AE-BF6B-221191942B61Q37147648-08D90564-6C58-4DCB-96C6-DE34C14E83A4Q37289567-FA30B297-1D96-4C07-BB1E-26D2180DB814Q37569179-E04E5D00-489C-49B7-A7CF-ACE2401C12E4Q37723467-0223DE47-5EEF-48B8-99BB-38FB71EAF414Q38083297-C0FD3C5D-AFE8-4500-9D9A-BED23FB8DAEDQ39127326-D288003B-F41C-4F38-8068-B66C3D9D799CQ39381227-31C09637-FF59-4EBA-9601-9E9450FF12F5Q40488232-DB66D8B7-85B0-4EAD-8BA3-4E6FD25AE85DQ40591120-A0BCC59D-9B04-4517-AC91-7D5EB106669AQ40604220-8F845BCA-D660-4B15-B6C4-32EFAFEFF5E9Q40689166-787FC701-BB9E-42FB-8166-C1BA3E723876Q41585335-F5B0D691-F78B-4CF8-A5BB-D6EA7D6C7763Q41677895-A843BF7A-8DA3-42CB-BD58-DC8195099391Q41771638-459480DC-8467-4CF8-B373-BC1C7575C0D0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antimicrobial resistance in Clostridium difficile.
@en
Antimicrobial resistance in Clostridium difficile.
@nl
type
label
Antimicrobial resistance in Clostridium difficile.
@en
Antimicrobial resistance in Clostridium difficile.
@nl
prefLabel
Antimicrobial resistance in Clostridium difficile.
@en
Antimicrobial resistance in Clostridium difficile.
@nl
P2093
P1476
Antimicrobial resistance in Clostridium difficile
@en
P2093
Carl Erik Nord
Haihui Huang
P304
P356
10.1016/J.IJANTIMICAG.2009.09.012
P577
2009-10-13T00:00:00Z